Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full-length tyrosinase protein in vaccinated melanoma patients

Journal of Immunological Methods

Volumn 266, Issue 1-2, 2002, Pages 87-103

  Housseau, Franck ^a   Lindsey, Kimberly R ^a   Oberholtzer, Samuel D ^a   Gonzales, Monica I ^a   Boutin, Paula ^b   Moorthy, Anitha K ^a   Shankara, Srinivas ^b   Roberts, Bruce L ^b   Topalian, Suzanne L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

Adenovirus; Dendritic cells; Immune monitoring; Quantitative real time RT PCR; Tyrosinase

Indexed keywords

ADENOVIRUS VECTOR; CANCER VACCINE; EPITOPE; GAMMA INTERFERON; HLA A1 ANTIGEN; MESSENGER RNA; MONOPHENOL MONOOXYGENASE;

ANTIGEN RECOGNITION; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; INCUBATION TIME; MELANOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; VACCINATION;

ADENOVIRIDAE; CANCER VACCINES; CELL LINE; CELLS, CULTURED; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MELANOMA; MONOPHENOL MONOOXYGENASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; TIME FACTORS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

ADENOVIRIDAE;

EID: 0036679624     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(02)00104-7     Document Type: Article

References (32)

1. Recombinant viruses as a tool for therapeutic vaccination against human cancers
2. Assays for monitoring cellular immune responses to active immunotherapy of cancer
3. Analysis of cellular immune response in the peripheral blood of mice using real time RT-PCR
4. Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells
5. N-linked carbohydrates in tyrosinase are required for its recognition by human MHC class II-restricted CD4+ T cells
6. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens
7. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination
8. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes
9. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
10. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1,-A2, and -A3 alleles
11. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development
12. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100
13. In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma
14. Tumor regression observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
15. Phase I study in advanced cancer patients of a diversified prime- and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
16. Status of activation of circulating vaccine-elicited CD8+ T cells
17. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte
18. Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients
19. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases
20. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: Implications of a novel approach for T cell monitoring in infectious and malignant diseases
21. A listing of human tumor antigens recognized by T cells
22. The promise of nucleic acid vaccines
23. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy
24. Progress in human tumor immunology and immunotherapy
25. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
26. Adenoviral transduction of human 'clinical grade' immature dendritic cells enhances costimulatory molecule expression and T-cell stimulatory capacity
27. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
28. Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction
29. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes
30. Human tumor antigens for cancer vaccine development
31. T-cell directed cancer vaccines: The melanoma model
32. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients